Kazia: AGILE Hurdle Missed but Significant Value Remains
Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download.
Read More
Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Kazia’spipeline includes two clinical-stage drug development candidates, and they are working to develop therapies across a range of oncology indications.
Kazia’s lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxal
Corporate Connect Research Report
DOWNLOAD RESEARCH
DOWNLOAD RESEARCH
ASX Code
KZA
Spotlight Videos
Kazia Therapeutics (ASX: KZA) – Webinar presentation
All Kazia Therapeutics Limited Content
News
Kazia Therapeutics (ASX: KZA) – Webinar presentation
James Garner - CEO & MD - Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of oncology indications.
Read More
Key Points To Remember When Investing in Biotech Companies
As part of his latest research report on the biotech sector, Corporate Connect analyst Marc Sinatra gives some insights into what to consider when making an investment in this space.
Read More
Due Diligence Webinar – Kazia Therapeutics
Presenter - James Garner CEO & Managing Director - Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Australia. Kazia's pipeline includes two clinical-stage drug development candidates and is working to develop therapies across a range of oncology indications.
Read More
A high quality pipeline of cancer drugs
James Garner - Managing Director & CEO - Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of oncology indications.
Read More
